Last reviewed · How we verify
NCT05828277
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Phase 1 trial testing repotrectinib (TPX-0005) in Locally Advanced Solid Tumor. Withdrawn.
31 August 2025
Quick facts
| Lead sponsor | Turning Point Therapeutics, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 28 July 2022 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across United States, Spain |
Drugs / interventions tested
- repotrectinib (TPX-0005) — full drug profile →
Conditions studied
- Locally Advanced Solid Tumor — all drugs for Locally Advanced Solid Tumor →
- Metastatic Solid Tumor — all drugs for Metastatic Solid Tumor →
Sponsor
Turning Point Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Locally Advanced Solid Tumor or Metastatic Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1 study to evaluate the effect of moderate or severe hepatic impairment on the PK of repotrectinib in patients with advanced cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05828277
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07213817 — A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of · Phase 1, PHASE2 · recruiting
- NCT06658353 — Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors · Phase 3 · recruiting
- NCT06349408 — IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
- NCT06415487 — ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor ( · Phase 1 · recruiting
- NCT06416007 — Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors · Phase 2 · recruiting
Other Turning Point Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05828303 — A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastat · Phase 1 · withdrawn
- NCT05001516 — Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors · Phase 1 · completed
- NCT05071183 — A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant S · Phase 1, PHASE2 · terminated
- NCT04849273 — A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC · Phase 1 · terminated
- NCT04094610 — A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05828277 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Turning Point Therapeutics, Inc.
- Last refreshed: 26 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05828277.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing